DRRX May 2024 3.000 call
| Previous close | 0.0800 |
| Open | 0.0700 |
| Bid | 0.0000 |
| Ask | 0.1000 |
| Strike | 3.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.0700 - 0.0800 |
| Contract range | N/A |
| Volume | |
| Open interest | 14 |
PR NewswireDURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update
DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its first quarter financial results on Monday, May 13, 2024. Management will also host a conference call and webcast with investors to discuss financial results and provide a corporate update at 4:30 pm Eastern Time. D
- PR Newswire
DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis
DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced acceptance of a late-breaking oral presentation at the European Association for the Study of the Liver (EASL) Congress 2024 to take place June 5-8, 2024 in Milan, Italy. The presentation will discuss data from the Company's Phase 2b AHFIRM trial, whi
Insider MonkeyDURECT Corporation (NASDAQ:DRRX) Q4 2023 Earnings Call Transcript
DURECT Corporation (NASDAQ:DRRX) Q4 2023 Earnings Call Transcript March 27, 2024 DURECT Corporation beats earnings expectations. Reported EPS is $-0.27, expectations were $-0.36. DRRX isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings and welcome to the DURECT Corporation Full […]
